Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.

Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G.

Drug Metab Dispos. 2011 Feb;39(2):215-27. doi: 10.1124/dmd.110.035386. Epub 2010 Nov 2. Erratum in: Drug Metab Dispos. 2011 Jun;39(6):1111.

2.

Disposition and metabolism of radiolabeled casopitant in humans.

Pellegatti M, Bordini E, Fizzotti P, Roberts A, Johnson BM.

Drug Metab Dispos. 2009 Aug;37(8):1635-45. doi: 10.1124/dmd.109.026781. Epub 2009 May 6.

3.

Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.

Prakash C, Kamel A, Gummerus J, Wilner K.

Drug Metab Dispos. 1997 Jul;25(7):863-72.

4.

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.

Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23.

5.
7.

Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.

Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, Scatina J.

Drug Metab Dispos. 2009 Jun;37(6):1219-25. doi: 10.1124/dmd.108.023861. Epub 2009 Mar 9.

8.

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.

Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH Jr, Piergies A, Karim A.

Drug Metab Dispos. 2000 Mar;28(3):308-14.

10.

Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.

Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM.

Drug Metab Dispos. 2001 Aug;29(8):1136-45.

11.

Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.

Polsky-Fisher SL, Vickers S, Cui D, Subramanian R, Arison BH, Agrawal NG, Goel TV, Vessey LK, Murphy MG, Lasseter KC, Simpson RC, Vega JM, Rodrigues AD.

Drug Metab Dispos. 2006 Jun;34(6):1004-11. Epub 2006 Mar 1.

12.

Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.

Dingemanse J, Hoever P, Hoch M, Treiber A, Wagner-Redeker W, Miraval T, Hopfgartner G, Shakeri-Nejad K.

Drug Metab Dispos. 2013 May;41(5):1046-59. doi: 10.1124/dmd.112.050120. Epub 2013 Feb 21.

13.

Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.

Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D.

Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1.

14.

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.

Kochansky CJ, Rippley RK, Yan KX, Song H, Wallace MA, Dean D, Jones AN, Lasseter K, Schwartz J, Vincent SH, Franklin RB, Wagner J.

Drug Metab Dispos. 2006 Sep;34(9):1457-61. Epub 2006 Jun 13.

15.

The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.

Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, Meuldermans W.

Drug Metab Dispos. 2007 Apr;35(4):554-65. Epub 2006 Aug 25.

17.

Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.

Schoenig GP, Hartnagel RE Jr, Osimitz TG, Llanso S.

Drug Metab Dispos. 1996 Feb;24(2):156-63.

PMID:
8742226
18.

Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.

Prakash C, Cui D, Potchoiba MJ, Butler T.

Drug Metab Dispos. 2007 Aug;35(8):1350-64. Epub 2007 May 11.

19.

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN.

Drug Metab Dispos. 2002 Apr;30(4):430-7.

20.

Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.

Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S.

Drug Metab Dispos. 2011 Feb;39(2):199-207. doi: 10.1124/dmd.110.035907. Epub 2010 Nov 2.

Supplemental Content

Support Center